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Abstract Pharmacovigilance is the scientific discipline
that copes with the continuous assessment of the safety
profile of marketed drugs. This assessment relies on
diverse data sources, which are routinely analysed to
identify the so-called “signals”, i.e. potential associa-
tions between drugs and adverse effects, that are un-
known or incompletely documented. Various computa-
tional methods have been proposed to support domain
experts in signal detection. However, recent compar-
ative studies illustrated that current methods exhibit
high false-positive rates, significantly variable perfor-
mance across different datasets used for analysis and
events of interest, but also complementarity in their
outcomes. In this regard, in order to reinforce accu-
rate and timely signal detection, we elaborated through
an agent-based approach towards systematic, joint ex-
ploitation of multiple heterogeneous signal detection
methods, data sources and other drug-related resources
under a common, integrated framework. The approach
relies on a multiagent system operating based on a
collaborative agent interaction protocol, aiming to im-
plement a comprehensive workflow that comprises of
method selection and execution, as well as outcomes’
aggregation, filtering, ranking and annotation. This pa-
per presents the design of the proposed multiagent sys-
tem, discusses implementation issues and demonstrates
the applicability of the proposed solution in an example
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signal detection scenario. This work constitutes a step
towards large-scale, integrated and knowledge-intensive
computational signal detection.
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1 Introduction
The importance of drug safety is widely recognised [1].
Pharmacovigilance encompasses all data gathering and
processing activities related with the detection, assess-
ment, understanding and prevention of adverse effects
throughout the entire lifecycle of drugs [2].
One of the most important aspects in the monitor-
ing of marketed drugs is the identification and analy-
sis of new, medically important findings, so-called sig-
nals that might influence the use of a medicine. Signals
have been defined1 by the Council for International Or-
ganisations of Medical Sciences (CIOMS) VIII Working
Group as “information that arises from one or multi-
ple sources (including observations and experiments),
which suggests a new potentially causal association, or
a new aspect of a known association, between an in-
tervention and an event or set of related events, either
adverse or beneficial, that is judged to be of sufficient
likelihood to justify verificatory action” [4]. In the scope
of this work, we focus on adverse events.
In the pre-market stage, clinical trials of newly de-
veloped drugs constitute the main procedure for identi-
1 For a list of comprehensive definitions in the domain of
pharmacovigilance the reader is referred to [3].
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fying Adverse Drug Reactions2 (ADRs) resulting from
their use. However, due to time constraints, the lim-
ited sample population size as well as potential bias,
clinical trials do not enable the detection of all possi-
ble ADRs. Consequently, post-marketing surveillance is
necessary to identify new or incompletely documented
ADRs throughout the time a drug is actively prescribed
[5]. Active and systematic surveillance requires constant
assessment of all drugs for any outcome [2].
Given the necessity to identify as early as possible
signals, it has become evident that all the available data
sources have to be explored [6]. In the post-marketing
context, these sources vary, spanning from spontaneous
reports, electronic health records [7], scientific litera-
ture [8], and even social media [9]. The availability of
this data deluge dictates the need to introduce high-
throughput computational methods that will enable ef-
ficient knowledge extraction and management, compen-
sating the underlying heterogeneity and complexity.
To this end, various computational signal detection
methods have been proposed to explore the above types
of data sources [10]. However, these methods are de-
signed for application in a single data source and typ-
ically demonstrate high false-positive rates in the pro-
vided results. In addition, the task of assessing the out-
comes of analysis methods is currently performed man-
ually and requires significant effort. Overall, accurate,
timely and evidence-based signal detection remains a
challenge [11].
The current work concerns integrated signal detec-
tion, i.e. a systematic, joint exploitation of multiple het-
erogeneous signal detection methods, data and other
drug-related resources under a common framework, ad-
dressing methods’ selection and execution, as well as
outcomes’ aggregation, filtering, ranking and annota-
tion. Heterogeneity refers both to the methods’ under-
lying computational models and the data that they can
analyse. This paper presents an agent-based approach
for the construction of a knowledge-intensive platform
to accommodate these requirements, relying on a mul-
tiagent system that operates based on a collaborative
agent interaction protocol.
The paper is structured as follows: In section 2, we
provide background information concerning computa-
tional signal detection and comment on the motivation
of this work. In section 3, we describe the challenges
that this work implies and we justify the adoption of
the agent paradigm. We then present the architecture of
the proposed multiagent system, including agent classes
2 ADR: response that is noxious and unintended, and that
occurs at doses normally used in humans for the prophylaxis,
diagnosis, or therapy of disease, or for the modification of
physiological function [3].
and the overall integrated signal detection strategy. In
section 4, we provide details for our prototype imple-
mentation as regards the material and the development
tools that have been employed. Equally important, we
also illustrate the functionality of the multiagent system
through an example signal detection scenario. In section
5, we discuss our contribution in comparison with re-
lated works and highlight current limitations and future
work plans. Finally, section 6 concludes the paper.
2 Computational Signal Detection: Background
and Motivation
Computational analysis methods constitute a well es-
tablished support tool for signal detection [10]. Com-
putationally extracted signals can be considered as po-
tential causal relations that have to be verified. As such,
they are perceived as early indications informing drug
safety experts for appraisal actions, which require the
review/analysis of scientific literature, clinical trial data,
biological properties of drugs, etc., before concluding at
causality.
The output of computational signal detection meth-
ods is a list of drug-event pairs, which shall be ideally
ranked based on significance factors (statistical or prob-
abilistic), in order to drive the focus of appraisal ac-
tions. Since these actions are typically performed man-
ually, they require significant effort and, given the large
amount of generated indications, they result in a bot-
tleneck in the pharmacovigilance process [12]. Thus, be-
sides highly accurate detection methods, filtering mech-
anisms are necessary, in order to exclude: (a) known
ADRs, but also (b) associations containing conditions
corresponding to the drugs’ indicated use, which can
be also generated as potential signals, according to the
data being explored.
As the volume of data for signal detection is con-
stantly increasing with new sources being considered for
analysis (like patient-generated content in social media
platforms), the need for advanced computational signal
detection frameworks becomes imperative [13]. Based
on their nature and the computational analysis that
they require, the main data sources for signal detection
can be categorised into: a) spontaneous reporting sys-
tems, b) structured, longitudinal observational health-
care databases, and c) unstructured / free-text data
sources.
In particular, spontaneous reporting systems (SRSs)
constitute the dominant source of signals through which
suspected cases are voluntarily reported by healthcare
professionals (and in some cases by patients) to reg-
ulatory authorities and other bodies. Prominent SRSs
are the Food and Drug Administration (FDA) Adverse
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Event Reporting System (FAERS [14]) in US, EudraVig-
ilance maintained by the European Medicines Agency
[15], and VigiBase R© maintained by the Uppsala Mon-
itoring Centre [16]. The main type of signal detection
methods for analysing SRS data relies on the statis-
tical investigation of “disproportionality” (i.e. assess-
ing whether a specific event is reported more frequently
for a drug than would be expected if randomly occur-
ring) [17]. Another category of methods exploiting SRS
data are the so-called “multivariate” [10], such as logis-
tic regression-based and unsupervised machine learning
methods, which are able to analyse more complex drug
safety incidents compared to disproportionality-based
methods.
Structured observational healthcare data originate
mostly from Electronic Health Record (EHR) and ad-
ministrative claim systems. These data sources have
been considered in terms of secondary use for the iden-
tification of potential causal relations between drugs
and adverse conditions [7], [18]. Compared to sponta-
neous reports, observational data contain more infor-
mation, such as diagnosis and lab examination results.
The corresponding signal detection methods typically
involve the application of data mining techniques in
large datasets [19]. A number of methods have been
also proposed having their origin from statistical epi-
demiology, relying on case-control design [20], cohort
design [21], self-controlled case series design [22], self-
controlled cohort design [23], etc. Notably, the Obser-
vational Medical Outcomes Partnership (OMOP) gath-
ered an open-source library of such methods [24].
In the category of unstructured free-text data, typ-
ical sources include clinical narratives, scientific liter-
ature and patient self-reports. Clinical narratives re-
main a significant part of EHR systems, in which in-
formation concerning diagnosis and patient treatment
(including drugs) is documented [25]. Scientific litera-
ture may also provide indications for pharmacovigilance
signals [12] as well as evidence to support the evalua-
tion of findings obtained by other sources. Patient self-
reports about drug concerns/problems that are shared
among networked communities using social media are
an emerging source of signals [26]. However, the subjec-
tive nature and the lack of quality control in the gener-
ated data constitute important limitations for reliable
signal detection. Independently of the data source that
is being employed, computational signal detection us-
ing unstructured text relies on information extraction
and natural language processing (NLP) techniques [27].
Interestingly, recent comparative studies of compu-
tational signal detection methods have highlighted [28]-
[31]: (a) high false-positive rates, (b) significantly vari-
able performance across different datasets used for anal-
ysis and events of interest, but also (c) complementar-
ity among methods’ outcomes. These findings reinforce
the argument for the joint exploration of as many data
sources as possible through diverse computational sig-
nal detection methods. Another argument for combined
signal detection is that potential signals replicated in
multiple data sources may indicate increased confidence
in establishing a causal relation among drugs and ad-
verse effects and, thus, they are more likely to be true.
For example, this hypothesis has been successfully eval-
uated in [32], combining EHR and SRS data.
To this end, the motivation of this work concerns
the design and development of a systematic framework
enabling large-scale combinatorial signal detection as
described in the following section.
3 An Agent-based Approach for Integrated
Signal Detection
3.1 Challenges and Adoption of the Agent Paradigm
Our view for computational signal detection concerns
an integrated framework in which joint exploitation of
multiple heterogenous drug safety data sources can be
performed through relevant computational signal detec-
tion methods, as well as other drug information sources.
However, this broader exploitation increases the com-
plexity of the signal detection procedure for the end-
users and requires a technical framework to be set.
More specifically, from the users’ perspective, the
technical complexity caused for example by many pa-
rameters offered by some detection models3, has to be
addressed. Similarly, users could be interested in ex-
ploring only specific data sources, e.g. based on their
origin, coverage and / or content, thus, selection shall
be facilitated. In this respect, support in study setup
and selection of the resources that will be used is im-
portant.
Since the focus in signal detection concerns new
ADRs, noisy indications (e.g. known ADRs or associ-
ations linking the drug with its indicated use) have to
be filtered by accessing reference knowledge. Given the
fact that computational signal detection methods typ-
ically generate many potential indications for ADRs,
the remaining findings shall be ranked to prioritise their
subsequent assessment by drug safety experts. In addi-
tion, supportive information on the findings would in-
crease their comprehension, beyond just providing sta-
tistical measures on each drug-event pair. Such informa-
3 An indicative example concerning the variety of analy-
sis options is illustrated in [33], in which 14 signal detection
methods were tested and the number of different combina-
tions of analysis parameters varied from 48 to 162.
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Fig. 1 Elaborated workflow for integrated signal detection.
tion may constitute, for example, the toxicity profile of
the drug of interest, recent relevant published studies,
as well as information about potentially relevant clini-
cal trials. At a lower level, technical challenges include
the development of efficient mechanisms for interfacing
with data sources and signal detection methods, as well
as aggregating and synthesising method outcomes.
In this regard, Figure 1 depicts the overall signal
detection workflow elaborated in this work, starting
from study setup and concluding with outcomes an-
notation and enrichment with supportive information.
For the implementation of this workflow, we elaborate
on a software platform, in order to address two major
aspects. First, the semantic harmonisation of key con-
cepts / information models of signal detection methods
available through the platform. Second, the aggrega-
tion of the methods’ outcomes and the assessment of
the findings’ strength. For the first part we developed
the Pharmacovigilance Signal Detectors Ontology (PV-
SDO), which has been presented in [34], while the sec-
ond part is addressed via a multiagent system that is
presented in the current paper.
We adopted the “software agent” paradigm, as it of-
fers a favourable way to consider complex systems with
multiple distinct and independent components. Agents
enable the aggregation of different functionalities in a
conceptually embodied and situated whole, while at
the same time may exhibit autonomous, social, reac-
tive and/or proactive features [35]. This offers appro-
priate abstractions for the design and development of
large systems of individual agents and of ways in which
agents may interact, while taking into account organi-
sational or macro-level issues. Especially through task
decomposition and coordination, software agents can
contribute in the accomplishment of complex goals and
tasks. In the current work, agents provided us with a
way of structuring a system around autonomous com-
municative elements [36], through which we develop
mechanisms for automating and improving signal detec-
tion in an integrated framework, supporting drug safety
experts in accomplishing this task.
Since our ultimate goal is the development of an ex-
tensible platform in which new methods, raw data and
other relevant data/information sources can be incor-
porated, the modularity and reusability offered by the
agent paradigm [37] enable us to design a sustainable
and scalable architecture comprising of diverse compo-
nents as presented in the following subsection.
3.2 System Architecture: Resources and Agent Classes
In order to implement the workflow presented in Fig. 1,
we defined a system architecture comprising of software
agents, non-agent software components, data / informa-
tion sources, and a knowledge component. Non-agent
software components correspond to implementations of
signal detection methods, while data sources provide
the raw data employed for signal detection (e.g. spon-
taneous reports, EHR data, etc.). Information sour-ces
provide reference data on known ADRs and other drug-
related information, while the knowledge component
corresponds to an ontology-based Semantic Registry
describing all the resources of the framework based on
PV-SDO [34].
We formulated a collaborative agent team, which
operates according to an agent interaction protocol that
we defined [38], corresponding to the implementation
of each step of the integrated signal detection workflow
of Fig. 1. In this regard, agents exploit the resources
available in the system, so that signal detection meth-
ods are appropriately selected and launched, using the
Semantic Registry, while their results are aggregated
and post-processed via filtering (to discard noisy indi-
cations) and ranking (based on their significance) mech-
anisms, using the reference ADR and drug information
sources, respectively.
Appropriate agent classes were defined to support
this functionality. Initially, the main principle for defin-
ing these classes was task decomposition and distri-
bution [39], so that each agent is delegated a specific
and simple task to accomplish, and the computational
burden underlying integrated signal detection is dis-
tributed among agents. In the overall analysis and de-
sign phase, we followed the principles of MOBMAS [40],
a comprehensive methodology that covers the main ac-
tivities of developing multiagent systems (analysis, mul-
tiagent organisation design, agent internal design, agent
interaction design, and agent architecture), which is rel-
evant with the development of ontology-based multia-
gent systems. Based on the collaborative agent interac-
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Fig. 2 The proposed system architecture for integrated signal detection.
tion protocol, agent activities are coordinated and re-
sult in a multiagent system that performs the proposed
integrated signal detection via teamwork.
Figure 2 depicts the proposed system architecture,
discriminating between an aggregation scheme and a
reasoning scheme. In this respect, let us consider that
the architecture comprises of h SRS-based signal detec-
tion methods denoted by the set:
SR = {SR1, SR2, . . . , SRh}, (1)
j methods appropriate for signal detection in structured
longitudinal observational healthcare data sources cor-
responding to:
OD = {OD1, OD2, . . . , ODj}, (2)
and k detection methods for unstructured text sources
denoted as:
UT = {UT1, UT2, . . . , UTk}. (3)
The architecture includes also means to access l
ADR reference data sources:
RS = {RS1, RS2, . . . , RSl}, (4)
as well as m drug information sources:
DI = {DI1, DI2, . . . , DIm}. (5)
O depicted in Figure 2 denotes the ontology-based
Semantic Registry of Signal Detection Resources [34].
The following agent classes were defined:
– User Agent : an interface agent responsible to sup-
port the end-user in defining and conducting an in-
tegrated signal detection experiment.
– Aggregation Agent : a mediator agent which controls
the agent interaction protocol.
– Methods Selection Agent : a wrapper agent which
queries O for appropriate signal detection methods
given a specific experiment.
– Signal Detection Agent : a wrapper agent capable of
receiving requests for signal detection (along with
specific analysis parameters), launching the respec-
tive signal detection method, and returning the out-
comes4.
– Filtering Agent : a processing agent capable of ac-
cessing ADR reference sources, in order to filter the
aggregated outcome provided by Signal Detection
Agents.
– Signal Ranking Agent : a processing agent capable of
applying diverse criteria/metrics, in order to rank
the results provided by the Filtering Agent.
4 Note that for each one of the considered computational
methods (1)-(3), a Signal Detection Agent is assigned.
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– Drug Information Agent : an information retrieval
agent capable of identifying supportive information
for the outcomes of the Signal Ranking Agent.
According to the behaviour that the above agent
classes have to exhibit, we addressed design issues at
the micro-level. For example, the Aggregation Agent
encapsulates a rule-based logic, in order to implement
the agent coordination protocol, while wrapper agents
(i.e. the Methods Selection Agent and Signal Detection
Agents) incorporate a translation mechanism capable
of converting agent requests to queries in the respec-
tive resources and encapsulating the obtained results
in an agent message.
Upon a new experiment definition, instances of the
above agent classes are launched to undertake the cor-
responding signal detection workflow5.
The behaviour of each agent is presented in the de-
scription of the aggregation and reasoning schemes, in
subsections 3.3 and 3.4, respectively.
3.3 Selection of Methods and Aggregation of
Outcomes
The proposed platform aims to support two diverse us-
age scenarios, i.e.: (a) signal detection without a specific
target on drugs or health outcomes, which is performed
routinely by drug safety authorities, and (b) targeted
signal detection concerning specific drugs and poten-
tial adverse effects, which is particularly interesting for
pharmaceutical companies as a mean to identify risks
for their marketed drugs.
Upon the definition of a new analysis experiment,
in the targeted signal detection scenario the user pro-
vides as input the target of the analysis (drug and/or
health outcome of interest). In addition, in both scenar-
ios, optional input parameters can be: (a) the resources
that will be employed in the experiment (i.e. the sources
of pharmacovigilance signals, the reference data sources
on known ADRs and the drug information sources), (b)
specific values of analysis/configuration parameters of-
fered by signal detection methods, such as the rule for
signal generation6, the time-at-risk7, etc., and (c) rank-
ing criteria to be employed for the prioritisation of the
5 This practice has been followed in the current experimen-
tal implementation. However, it is also possible to share agent
instances across experiments (such as the Drug Information
Agent, the Filtering Agent, the Signal Ranking Agent, etc.).
6 A condition or a set of conditions that needs to be satisfied
by a signal detection method, in order to generate a signal.
7 The period of time a patient is considered to be ‘at-risk’
and, therefore, counting occurrence of conditions as potential
events.
generated signals. If the above optional input parame-
ters are not defined, then: (a) all the resources available
in the platform will be employed, (b) the default values
for analysis/configuration parameters defined for each
signal detection method will be used, and (c) all the
available ranking criteria will be employed, respectively.
Although explicit, the above inputs pose also im-
plicit requirements (e.g. which methods can support the
signal generation criterion) for the experiment that will
be conducted. Based on these inputs, the selection of
the signal detection methods that will be used in a given
signal detection experiment is performed by querying
the Semantic Registry O (Fig. 2). O defines the capa-
bilities, interfaces and parameterisation options of each
signal detection method, according to expert domain
knowledge and the specifications provided by the re-
spective developers. The respective query is forwarded
to the Methods Selection Agent by the Aggregation Agent,
given the input parameters provided by the User Agent.
In particular, let C denote the set of input param-
eters that the user defined for a given experiment:
C = {C1, C2, . . . , Cq}, (6)
and assume that C is met by a set of n detection meth-
ods:
P = {P1, P2, . . . , Pn}, (7)
with P denoting a subset of the available ones, i.e. P ⊆
(SR ∪ OD ∪ UT). In particular, P is determined by
applying a matchmaking query Q, between the input
parameters C and the registered detection methods in
O, through the Methods Selection Agent :
Q : C
O−→ P. (8)
According to P, the corresponding Signal Detection
Agents are requested by the Aggregation Agent to in-
voke the respective signal detection methods, taking
into account potential input parameters defined in (6).
The analysis results obtained from each Signal Detec-
tion Agent are gathered by the Aggregation Agent, and
correspond to a set R, with:
R = {R1,R2, . . . ,Rn}, (9)
where Ri, i = {1, . . . , n} denotes in turn a set of po-
tential signals obtained from the Pi detection method
(7). In addition, elements of R may be equal to ∅, in
case where no indication for signals is obtained by the
respective detection method(s). Next, the Aggregation
Agent encodes the obtained outcomes R into a uni-
form representation, keeping also provenance informa-
tion (i.e. which methods and data were employed and
with what parameter values) regarding the origin of
each Ri.
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3.4 Filtering, Prioritisation and Annotation of
Outcomes
This part concerns the reasoning scheme, employing the
available reference ADR and drug information sources,
i.e. RS (4), DI (5), respectively, in order to: (a) filter R
(9) for noisy indications and, subsequently, (b) priori-
tise the remaining novel indications (if any), according
to ranking criteria.
In this regard, first, the Aggregation Agent provides
its results to the Filtering Agent, which implements a
novelty assessment mechanism f1, so that from each Ri
a subset R′i (R
′
i ⊆ Ri) is produced containing only the
novel indications:
f1 : R
RS−→ R′. (10)
As a second step, the Aggregation Agent provides R′
to the Signal Ranking Agent, which is in turn capable
of applying a prioritisation mechanism f2 on R′ based
on a set of metrics that is denoted as:
PR = {PR1, PR2, . . . , PRw}. (11)
In PR, we discriminate two types of metrics/criteria:
1. computational metrics, e.g. prioritising the common
results within the first k among those provided by
the signal detection methods employed in a given
analysis experiment, and
2. domain criteria, like those proposed for implement-
ing triage schemas in signal detection [41], e.g. ADR
seriousness, newer drugs, data originated from mul-
tiple countries, etc.
The information to apply domain criteria may be found
either in drug information sources (e.g. the drug re-
lease date), or in the raw data employed for signal de-
tection. As an example of the latter case, spontaneous
reports typically contain a characterisation of the re-
ported event as serious or not, and may further spec-
ify seriousness according to the result (e.g. death, life
threatening condition, hospitalisation, etc.). Thus, the
Signal Ranking Agent embodies the required knowl-
edge, in order to interpret such domain criteria.
Let us consider that the end-user defined in C (6)
a set of ranking metrics PR′ (with PR′ ⊆ PR) to be
applied in a given experiment.
Then, R# corresponds to the ranking of R′ based
on PR′, i.e. R# ≡ rank(R′)|PR′, by applying f2, i.e.:
f2 : R′ PR
′
−→ R#. (12)
The final outcome FO provided to the end-user via
the User Agent comprises of R# along with support
information obtained from the Drug Information Agent
through DI per R# element, if available, i.e.:
FO = R# ∪DIR# . (13)
Figure 3 illustrates via a sequence diagram the col-
laborative agent interaction protocol implementing the
above signal detection strategy within the integrated
framework.
4 Implementation and Example Scenario
4.1 Material
At the current stage, the development of the proposed
integrated signal detection framework relies on publicly
available resources. In particular, we employed the fol-
lowing:
– Sources of raw data for signal detection: (a) the
FAERS spontaneous reporting system; (b) PubMed,
the reference bibliographic database in the life sci-
ences, and (c) Twitter, a popular micro-blogging
platform.
– Reference data sources for filtering the outcomes of
signal detection methods: (a) the Side Effect Re-
source (SIDER) [42], containing information on mar-
keted medicines and their recorded ADRs, which is
extracted from public documents and package in-
serts, and (b) DrugBank [43], since it provides rich
information on drug-drug interactions. Both SIDER
and DrugBank provide also the indications for each
drug’s use, which is another type of information em-
ployed for filtering.
– Drug information sources for supporting evidence
on novel findings: (a) ChEMBL [44], which contains
2-D structures, calculated properties and abstracted
bioactivities of drugs, but also (b) DrugBank, as it
combines drug data (i.e. chemical, pharmacological
and pharmaceutical) with comprehensive drug tar-
get information (i.e. sequence, structure, and path-
way), along with biointeraction information.
– Signal Detection Methods: implementations of well-
known methods contained in the open-source PhViD
R package [45], and an in-house signal detection
method appropriate for unstructured text.
– Semantic Registry : PV-SDO [34], an ontology ex-
pressed in OWL2 (Web Ontology Language 2) [46],
and populated with sample signal detection method
implementations, and the reference drug data and
information resources mentioned above.
While further resources will be elaborated in sub-
sequent stages of this development, the above mate-
rial has been considered adequate for a proof-of-concept
prototype implementation.
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Fig. 3 A partial view of the elaborated agent interaction protocol (for simplicity, only agents are depicted).
4.2 Development Aspects
Access to the resources mentioned in subsection 4.1 has
been realised programmatically. In particular, FAERS
data are retrieved through the openFDA Application
Programming Interface (API) [47], access to PubMed
data relies on the Web services provided by Europe
PubMed Central [48], and Twitter posts are retrieved
through the available REST (Representational State
Transfer) APIs [49]. Access to SIDER, DrugBank and
ChEMBL is made through the SPARQL (SPARQL Pro-
tocol and RDF Query Language) endpoints [50], avail-
able from Bio2RDF [51].
The multiagent system implementation is based on
the Java Agent DEvelopment framework (JADE) [52],
providing besides open source development tools, the
necessary agent execution environment. JADE is com-
pliant with the specifications for interoperable multia-
gent systems released by the Foundation for Intelligent
Physical Agents (FIPA) [53].
Signal Detection Agents invoke the respective signal
detection methods via Rserve [54], a TCP/IP server al-
lowing for third-party software to use R from various
languages and without the need to initialise R or link
against the R library. Upon initiation, each Signal De-
tection Agent is registered with the Directory Facilita-
tor, a standard agent contained in the FIPA Abstract
Architecture [55], which provides “yellow page” services
for the agents of the platform. Thus, the Aggregation
Agent queries the JADE built-in Directory Facilitator
to obtain the list of relevant Signal Detection Agents,
according to the analysis scenario.
In the current prototype, knowledge embodied in
the Signal Ranking Agent for the application and in-
terpretation of domain criteria used for signal ranking,
such as seriousness, is represented via a set of simple
rules (e.g. to encode that death is more severe than
hospitalisation). Although this is a rather simplistic ap-
proach, a generic resource providing this kind of knowl-
edge is not currently available.
Agent communication relies on message exchange.
Messages are represented in the relevant FIPA stan-
dards for agent communication, which set out the en-
coding, the semantics and the pragmatics of messages.
In this regard, messages are structured according to the
FIPA ACL Message Structure Specification [56], and
are built upon the FIPA Communicative Act Library
(e.g. request, inform, agree, etc.) [57]. The messages’
content relies on FIPA-SL [58], and on a basic appli-
cation ontology that we defined. This JADE-specific
ontology contains the respective agent actions and the
predicates to facilitate agent communication, according
to the methodology proposed in JADE and using the
Ontology BeanGenerator tool [59].
While various open-source implementations of sig-
nal detection methods are available for SRS and struc-
tured observational data, the availability of implemen-
tations for unstructured text-based signal detection meth-
ods is limited for the moment. Thus, we developed a
simple signal detection method relying on the clini-
cal Text Analysis and Knowledge Extraction System
(cTAKES) [60], and on its built-in Unified Medical Lan-
guage System (UMLS) [61] Annotator, to identify drug-
related terms and effects within PubMed abstracts and
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Twitter posts (namely, VigiText). Notably, cTAKES
is built upon the Unstructured Information Manage-
ment Architecture (UIMA) [62], thus, the development
of VigiText follows an established standard for manag-
ing unstructured data.
We illustrate the functionality of the proposed mul-
tiagent system via the following example signal detec-
tion scenario.
4.3 Example Scenario
Let us focus on a targeted signal detection scenario and
assume that the proposed platform integrates through
its multiagent system the following signal detection meth-
ods8:
– SRS-based detection methods9: BCPNN, GPS, PRR, and
ROR.
– Observational data detection methods10: ICTPD and
LGPS.
– Unstructured text detection methods: VigiText.
In this case, (1)-(3) correspond to:
SR = {BCPNN, GPS, PRR, ROR},
OD = {ICTPD, LGPS}, and
UT = {VigiText}, respectively.
Also, the Filtering Agent is capable of querying Drug-
Bank and SIDER, in order to filter the obtained out-
comes from known ADRs and findings that correspond
to the drug’s indicated use, while the Drug Information
Agent can connect to ChEMBL and DrugBank, in order to
obtain complementary drug information. Thus, in the
scope of this scenario, (4)-(5) correspond to:
RS = {SIDER, DrugBank} and
DI = {ChEMBL, DrugBank}, respectively.
A safety expert working for a pharmaceutical com-
pany wishes to search for potential signals concerning
Drug X, a new drug of the company which has been
quite recently made available in the market. Thus, (s)he
employs the resources of the platform to analyse data
from an observational healthcare database and the re-
ports available in FAERS. The user is prompted by the
User Agent to provide the input for this analysis (cf.
subsection 3.3). Besides Drug X, let us consider that
8 For the sake of simplicity and for illustration purposes,
we consider a limited number of detection methods and refer
to fictitious data in this example.
9 Methods contained in [45]. BCPNN: Bayesian Confidence
Propagation Neural Network, GPS: Gamma Poisson Shrink-
age, PRR: Proportional Reporting Ratio, ROR: Reporting Odds
Ratio.
10 Methods available at [63]. ICTPD: Information Compo-
nent Temporal Pattern Discovery, LGPS: Longitudinal Gamma
Poisson Shrinkage.
(s)he defines for SRS-based detection methods the de-
cision rule for signal generation to be "more than 3
reports", while for the OD-based detection methods
(s)he sets the value of the "Time-at-risk" parameter
to be "length -
of exposure+30days". Thus, (6) can be rewritten as:
C = {Target="Drug-X",Methods="SR, OD",
SR Analysis Criterion :
Signal generation condition=">3 reports",
OD Analysis Criterion :
Time-at-risk="length of exposure+30days"}.
Assuming that the considered ICTPD implementa-
tion does not support the defined value for Time-at-risk,
a fact that is captured in the PV-SDO ontology, ICTPD
is implicitly excluded from the analysis experiment as
indicated by the Methods Selection Agent. Thus, (9)
corresponds to:
P = {BCPNN, GPS, PRR, ROR, LGPS}.
Launching a Signal Detection Agent for each detec-
tion method of P, let us assume that the aggregation
outcome given by (9) for the targeted Drug X is:
R = {RBCPNN, RGPS, RPRR, RROR, RLGPS}, with11:
RBCPNN = {Drug X-MI,Drug X-Neutropenia},
RGPS = {Drug X-MI},
RPRR = ∅,
RROR = {Drug X-ARF} and
RLGPS = {Drug X-MI}.
The Filtering Agent performs SPARQL queries to
DrugBank and SIDER such as the one presented in Fig.
4, in order to identify which of the above indications
shall be discarded. Let us assume that MI is a registered
ADR for Drug X in both DrugBank and SIDER. Thus, it
is discarded from R. As a result, R′ comprises of:
R′BCPNN = {Drug X-Neutropenia} and
R′ROR = {Drug X-ARF}, while
R′GPS = R
′
PRR = R
′
LGPS = ∅.
In order to prioritise the remaining indications, i.e.
Neutropenia and ARF, the user selects to employ the
ADR seriousness criterion, i.e. PR′ = {Seriousness}.
Assuming that ARF appears to result in more serious ef-
fects than Neutropenia in the analysed data (e.g. more
deaths have been reported with ARF), as provided by
the Signal Ranking Agent, Drug X-ARF is ranked prior
to Drug X-Neutropenia, i.e.:
R# = {Drug X-ARF, Drug X-Neutropenia}.
Finally, the Drug Information Agent obtains the en-
tire biochemical profile of Drug X and its biointerac-
tions by querying ChEMBL and DrugBank, respectively.
11 ARF: Acute Renal Failure, MI: Myocardial Infarction.
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Fig. 4 Indicative SPARQL query to assess whether Myocardial Infarction is a known ADR for drug X.
This information is attached to R# to formulate the fi-
nal outcome FO as in (13), also annotated with prove-
nance information for the experiment.
For illustration purposes, the above scenario refers
to fictitious data and it is rather oversimplified, since
typically the outcome of a signal detection method re-
turns a long list of drug-event pairs, which shall be fur-
ther considered for a potential causal relation. Never-
theless, it provides a comprehensive view of the agent
interaction protocol and the scope of integrated signal
detection that we introduced in this paper.
Notably, taking advantage of the proactive nature
of agents [35], the above drug safety screening scenario
may be executed as a background process. In this re-
spect, the user is notified promptly as soon as indica-
tions for signals are identified. Similarly, in the scenario
of screening for signals without a specific target, the
process shall be iteratively executed, when new data
become available.
5 Discussion
5.1 Contribution of this Work
This study elaborated on the design and development of
advanced IT mechanisms to leverage pharmacovigilance
signal detection. Timely and accurate signal detection
is of outmost importance in the scope of an active drug
surveillance system [64]. A number of quite recent, very
significant drug safety issues illustrated that adverse ef-
fects of drugs may be detected too late, when millions
of patients have already been exposed. To this end, the
investigation of diverse data sources via different analy-
sis methods for signal detection can contribute in more
timely and accurate findings [6].
In accordance with this perspective, the current work
introduced integrated signal detection, i.e. jointly ex-
ploiting multiple heterogeneous signal detection meth-
ods, data and other drug-related resources under a com-
mon framework, in order to strengthen the reliability
and coverage of the analysis outcomes. Besides out-
comes’ aggregation, the proposed approach included
their filtering, ranking and annotation, aiming to sup-
port drug safety experts in assessing and prioritising the
results. To this end, we take into account both compu-
tational metrics and domain criteria in order to priori-
tise the findings, while we also seek existing knowledge
for filtering noisy indications from relevant linked-data
based repositories.
Our research was built upon current systematic ef-
forts in the field, as we relied on available implemen-
tations of signal detection methods, as well as publicly
available drug safety related data and resources. The
idea of exploring and comparing different types of phar-
macovigilance signal detection methods has been pin-
pointed in the literature [32], [65]. However, we elabo-
rated on a systematic framework aiming to explore this
perspective at large-scale.
The multiagent system that has been proposed pro-
vides the basis for developing a platform to conduct
integrated signal detection. We defined a collaborative
agent integration protocol, in order to coordinate agent
activities and implement the workflow for integrated
signal detection. Thanks to the modularity and scala-
bility offered by the agent paradigm [37], we are able to
replicate our current approach and extend its capabili-
ties by integrating additional detection methods in the
platform.
5.2 Related Work
In the field of drug safety surveillance, various system-
atic initiatives have been recently formulated. In partic-
ular, the FDA-funded Mini-Sentinel project elaborates
on designing safety assessments using multiple existing
electronic healthcare data systems, developing and eval-
uating scientific methods to increase the precision of de-
tection techniques, while also identifying and address-
A Multiagent System for Integrated Detection of Pharmacovigilance Signals 11
ing barriers and challenges to build an advanced sys-
tem for active safety surveillance [66]. Similarly, OMOP
implemented and evaluated signal detection methods
for longitudinal observational data [24]. More recently,
the Observational Health Data Sciences and Informat-
ics (OHDSI) program has been established as a multi-
stakeholder, interdisciplinary collaborative to bring out
the value of health data through large-scale analytics
[67].
In addition, the EU-ADR Web Platform relies on
the exploitation of EHR data collected within a large-
scale European initiative [68]. Data are mined for spe-
cific drug events, which are then correlated with litera-
ture, protein and pathway data, resulting in a rich drug-
event dataset. Advanced distributed computing meth-
ods based on workflow technologies are tailored to co-
ordinate the execution of data-mining and statistical
analysis tasks.
Contrary to the above-mentioned important initia-
tives, we consider signal detection in an integrative frame-
work that involves multiple heterogeneous data sources
and detection methods, rather than focusing on a spe-
cific method applied on multiple sources of the same
kind, or on diverse methods applied on a specific data
source for benchmarking [13]. In this respect, we adopted
the agent paradigm as the enabling technology for the
development of an integrated platform, due to its proac-
tive, reactive and social nature. These features enabled
us to design and implement a novel collaborative mul-
tiagent system for signal detection, relying on appro-
priate mechanisms to automate and improve existing
tasks [36], that drug safety experts typically have to
undertake manually.
The agent paradigm has been successfully employed
in healthcare in various cases [37], with applications
spanning from decision support systems [69], disease
monitoring [70], telehealth services [71], ambient intelli-
gence and independent living [72], integration of hetero-
geneous biomedical systems [73], cross-organisational
workflow management [74], planning and resource al-
location [75], to evaluation of medical systems [76]. Via
this work, we illustrate a new application domain of
agent technologies in life sciences, i.e. pharmacovigi-
lance.
To the best of our knowledge, an agent-based per-
spective on the domain of drug safety has been only
explored in [77], in which a multiagent framework was
proposed for early detection of ADRs using electronic
patient data distributed across different sources and lo-
cations. The framework relied on intelligent agents em-
ploying fuzzy logic to represent, interpret, and compute
imprecise and subjective cues that are commonly en-
countered in ADR identification, as well as to retrieve
prior experiences by evaluating the extent of matching
between the current situation and a past experience.
Contrary to [77], in the current paper we introduced
an agent-based approach for the joint exploitation of
multiple, diverse and existing signal detection methods,
which are designed to analyse different types of signal
sources, under an integrated framework.
From a technical perspective, given that the pro-
posed multiagent system relies on semantic resources,
a notable work is the BioSTORM system [78]. BioS-
TORM elaborated on ontology-based, end-to-end de-
ployment of JADE-based agent systems by exploiting
diverse surveillance methods. While BioSTORM shares
some architectural similarities with the proposed sys-
tem, it was created for a different purpose/domain than
drug safety that was our focus. In terms of its general
rationale, our system shares some common attributes
with the DeepQA architecture [79]. DeepQA exploits
multiple methods for analysing natural language, iden-
tifying sources, finding and generating hypotheses, find-
ing and scoring evidence, as well as merging and ranking
hypotheses. Nevertheless, DeepQA is a general-purpose
massively parallel probabilistic evidence-based architec-
ture having its focus on unstructured/free-text data
based on UIMA, while our work relies on both struc-
tured and unstructured resources focusing on a specific
application domain.
5.3 Challenges and Future Work
Using a first prototype, we are currently elaborating on
particular case studies to illustrate the added value of
the proposed approach. Defined in collaboration with
drug safety experts, these studies concern drugs and
adverse effects that are quite rare, as well as new drugs
placed in the market, e.g. new anticoagulants, and their
association with specific adverse effects. In this regard,
the preliminary analysis reveals some “echoing” find-
ings across the diverse data sources explored, i.e. the
same signals are discovered in multiple data sources
and by multiple detection methods. This may indicate
the means of strengthening the outcomes provided by
signal detection methods applied separately, since repli-
cated signals obtained from diverse methods and data
sources may indicate more probable causal associations
between drugs and adverse effects.
Given the uncertainty of the results that signal de-
tection methods provide, approaches for fusing knowl-
edge under uncertainty are being investigated [80]. We
are also considering an agent-based voting scheme [81],
which will enable us to pursuit signal prioritisation by
applying multiple ranking criteria and measuring the
strength of signals in a comparative fashion. Overall,
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combining methods and their results in order to im-
prove accuracy, confidence, or speed such as the ap-
proach employed in DeepQA [79], is a part of the de-
veloped system that requires further research.
In terms of development, we find the potential to
assess whether BioSTORM could be applicable in the
particular application domain interesting [78]. In ad-
dition, in the current implementation, the Signal De-
tection Agents are handling the R output of the re-
spective detection methods. Signal detection methods
exposed through standardised, machine readable inter-
faces, would provide a more systematic solution. To this
end, we explore comprehensive frameworks for integrat-
ing R code in third-party applications, such as DeployR
[82]. Enriching and advancing the knowledge according
to which the Signal Ranking Agent applies domain cri-
teria, requires further research and development.
Up to now, we experimented with signal detection
methods that are available in the PhVid R package [45].
Further methods will be integrated in the subsequent
implementation phase, such as those contained in the
OMOP Methods Library [63]. Along this line, we aim
to elaborate on additional data sources for signal de-
tection and, particularly work with structured observa-
tional data. We are also elaborating on mechanisms for
social media screening, since patient self-reports may
provide unique insights, especially for drugs used in the
treatment of rare diseases, the feedback for which is
limited.
In the scope of active drug safety surveillance [64],
signal detection is a continuous and demanding process.
From the computational viewpoint, taking into account
the complexity posed by jointly exploiting multiple sig-
nal detection methods and drug-related resources under
the integrated signal detection approach that we intro-
duced, deploying and executing the proposed multia-
gent system in a cloud infrastructure is being considered
as a future step [83]. This would accommodate the re-
quired power, reliability and scalability for a large-scale
deployment accounting for additional signal detection
methods and drug safety resources.
6 Conclusions
deep This paper illustrated the application of the mul-
tiagent paradigm for systematically pursuing pharma-
covigilance signal detection within an integrated frame-
work. A formal agent collaboration strategy was pro-
posed, taking into account methods’ selection, aggrega-
tion of methods’ outcomes, and subsequently filtering
known ADRs and ranking the remaining potential sig-
nals for prioritisation. Relying on various data, infor-
mation and knowledge sources along with a number of
signal detection method implementations, our proof-of-
concept development illustrated that the agent-based
approach is valid for such an integration. We are cur-
rently elaborating to integrate further resources and
illustrate the added value in signal detection through
concrete case studies. Overall, this work constitutes a
step toward large-scale, knowledge-intensive computa-
tional signal detection.
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